---
title: ""
---

### In trial, prioritised, and rejected interventions

<br />

#### In trial

::: {.callout-tip icon="false" collapse="true"}
## Baricitinib

[Full assessment](drugs/baricitinib.qmd)

Reviewed:  24-04-2023 \ \ \ \ In trial:  tbc

Baricitinib selectively and reversibly inhibits the Janus-associated tyrosine kinases JAK1 and JAK2.
:::

::: {.callout-tip icon="false" collapse="true"}
## Simvaststain

[Full assessment](drugs/simvastatin.qmd)

Reviewed:  24-04-2023 \ \ \ \ In trial:  tbc

Simvastatin competitively inhibits 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, an enzyme involved in cholesterol synthesis.
:::

<br />

#### Prioritised

::: {.callout-caution icon="false" collapse="true"}
## Atibuclimab

[Full assessment](drugs/atibuclimab.qmd)

Reviewed:  24-04-2023 \ \ \ \ Priority:  1

Atibuclimab (IC14) is a chimeric CD14 antibody
:::

::: {.callout-caution icon="false" collapse="true"}
## Tocilizumab

[Full assessment](drugs/tocilizumab.qmd)

Reviewed:  24-04-2023 \ \ \ \ Priority:  1

Tocilizumab is a recombinant humanised monoclonal antibody that binds to interleukin-6 receptors thereby blocking the activity of pro-inflammatory cytokines.
:::

::: {.callout-caution icon="false" collapse="true"}
## Vilobelimab

[Full assessment](drugs/vilobelimab.qmd)

Reviewed:  24-04-2023 \ \ \ \ Priority:  1

Vilobelimab is a human-mouse chimeric IgG4 kappa antibody that targets human C5a in plasma.
:::

<br />

#### Rejected - under review

::: {.callout-important icon="false" collapse="true"}
## Belapectin 

*nebulised/inhaled*

Reviewed:  24-04-2023

Rejected on the basis of insufficient evidence for efficacy.

Belapectin is a Galectin-3 (Gal-3) inhibitor.
:::

::: {.callout-important icon="false" collapse="true"}
## Dilmapimod

Reviewed:  24-04-2023

Rejected on the basis of insufficient evidence for efficacy.

Dilmapimod is a potent p38 MAPK inhibitor.
:::

::: {.callout-important icon="false" collapse="true"}
## Fingolimod

Reviewed:  24-04-2023

Rejected on the basis of insufficient evidence for efficacy.

Fingolimod is a sphingosine 1-phosphate (S1P) antagonist an a pak1 activator.
:::

::: {.callout-important icon="false" collapse="true"}
## Furosemide

*nebulised/inhaled*

Reviewed:  24-04-2023

Rejected on the basis of insufficient evidence for efficacy.

Furosemide is a potent and orally active inhibitor of Na+/K+/2Cl- (NKCC) cotransporter, NKCC1 and NKCC2. Furosemide is also a GABAA receptor antagonist.
:::

::: {.callout-important icon="false" collapse="true"}
## Imatinib

Reviewed:  24-04-2023

Rejected on the basis of insufficient evidence for efficacy.

Imatinib is an orally bioavailable tyrosine kinase inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity.
:::

::: {.callout-important icon="false" collapse="true"}
## Macrolides

Reviewed:  24-04-2023

Rejected on the basis of insufficient evidence for efficacy.

Macrolides are protein synthesis inhibitors. 
:::

<br />

#### Rejected - not under review

::: {.callout-important icon="false" collapse="true"}
## Aspirin

Reviewed:  24-04-2023

Rejected on the basis of prevalence of use in the target population.

Aspirin is an orally active, potent and irreversible inhibitor of cyclooxygenase COX-1 and COX-2. Aspirin also inhibits platelet prostaglandin synthetase. 
:::

::: {.callout-important icon="false" collapse="true"}
## Citrulline

Reviewed:  24-04-2023

Rejected on the basis of insufficient evidence for efficacy.

Citrulline is an Î±-amino acid.
:::

::: {.callout-important icon="false" collapse="true"}
## Dexamethasone

Reviewed:  24-04-2023

Rejected on the basis of ongoing or proposed trials.

Dexamethasone is a glucocorticoid receptor agonist. Dexamethasone also significantly decreases CD11b, CD18, and CD62L expression on neutrophils, and CD11b and CD18 expression on monocytes. 
:::

::: {.callout-important icon="false" collapse="true"}
## N-acetyl-cysteine

*nebulised/inhaled*

Reviewed:  24-04-2023

Rejected on the basis of insufficient evidence for efficacy.

N-Acetylcysteine is a mucolytic agent and a ROS inhibitor.
:::

::: {.callout-important icon="false" collapse="true"}
## Streptokinase

*nebulised/inhaled*

Reviewed:  24-04-2023

Rejected on the basis of insufficient evidence for efficacy.

Streptokinase is a bacteria-derived protein and a plasminogen activator.
:::








